Live Breaking News & Updates on Regenxbio inc

Stay informed with the latest breaking news from Regenxbio inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Regenxbio inc and stay connected to the pulse of your community

Regenxbio (RGNX) Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314

Regenxbio (RGNX) Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , Jeffreys-heier , European-medicines-agency , Regenxbio-inc , Retina-research-at-ophthalmic-consultants , Drug-administration , Vitreoretinal-service , Nasdaq , Chief-executive-officer

RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Boston , Massachusetts , United-states , Jeffreys-heier , European-medicines-agency , Regenxbio-inc , Drug-administration , Ophthalmic-consultants , Vascular-endothelial-growth-factor-agents , Retinal-disease , From-bench

REGENXBIO (NASDAQ:RGNX) Shares Down 2%

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) dropped 2% on Thursday . The stock traded as low as $21.67 and last traded at $21.74. Approximately 19,963 shares traded hands during trading, a decline of 97% from the average daily volume of 791,242 shares. The stock had previously closed at $22.18. Wall Street Analysts Forecast Growth […]

Canada , Kentucky , United-states , Arizona , Raymond-james , Steve-pakola , Leerink-partnrs , Company-profile , Regenxbio-inc , Manufacturers-life-insurance-company , Nasdaq , Technology-platform

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript

REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.43 EPS, expectations were $-1.27. REGENXBIO Inc.

Orlando , Florida , United-states , Japan , Hawaii , America , Hawaiian , Annabel-samimy , Gena-wang , Danielle-brill , Lisa-walter , Vikram-purohit

REGENXBIO (NASDAQ:RGNX) Shares Gap Down After Earnings Miss

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s share price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $20.02, but opened at $19.01. REGENXBIO shares last traded at $19.31, with a volume of 61,047 shares trading hands. The biotechnology company reported ($1.43) […]

Kentucky , United-states , Arizona , Stifel-nicolaus , Raymond-james , William-blair , Nasdaq , Kokusai-asset-management-co , Securities-exchange-commission , Financial-services-group-inc , Manufacturers-life-insurance-company , Technology-platform

REGENXBIO (NASDAQ:RGNX) Shares Gap Down on Disappointing Earnings

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $20.02, but opened at $19.01. REGENXBIO shares last traded at $19.31, with a volume of 61,047 shares trading hands. The biotechnology company reported ($1.43) EPS for […]

Canada , Stifel-nicolaus , Raymond-james , William-blair , Royal-bank , Regenxbio-inc , Technology-platform , Northwestern-mutual-wealth-management-co , Headlands-technologies , Nasdaq , Financial-services-group-inc , Securities-exchange-commission

REGENXBIO (NASDAQ:RGNX) Shares Gap Down on Disappointing Earnings

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $20.02, but opened at $19.01. REGENXBIO shares last traded at $19.31, with a volume of 61,047 shares trading hands. The biotechnology company reported ($1.43) EPS for […]

Canada , William-blair , Raymond-james , Stifel-nicolaus , Nasdaq , Financial-services-group-inc , Securities-exchange-commission , Royal-bank , Regenxbio-inc , Technology-platform , Northwestern-mutual-wealth-management-co , Headlands-technologies

Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights

Strategic Focus and Pipeline Advancements Amid Financial Prudence

Technology-platform , Regenxbio-inc , Rocket-pharmaceuticals , Financial-performance , Priority-review-voucher , Ultragenyx-pharmaceutical , Operational-highlights , Egenxbio-inc , Egenxbio , Ivotal-trials , Y-2023

REGENXBIO (NASDAQ:RGNX) Trading Up 7.8%

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s share price rose 7.8% during mid-day trading on Monday . The stock traded as high as $18.77 and last traded at $18.77. Approximately 163,095 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 678,608 shares. The stock had previously closed at […]

Steve-pakola , Raymond-james , William-blair , Stifel-nicolaus , Redmile-group , Regenxbio-inc , Blackrock-inc , Goldman-sachs-group-inc , Technology-platform , Nasdaq , Securities-exchange-commission , Get-free-report

REGENXBIO (NASDAQ:RGNX) Trading Up 7.8%

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report)’s stock price shot up 7.8% on Monday . The company traded as high as $18.77 and last traded at $18.77. 163,095 shares were traded during trading, a decline of 76% from the average session volume of 678,608 shares. The stock had previously closed at $17.41. Wall Street Analyst […]

Canada , Raymond-james , William-blair , Stifel-nicolaus , Royal-bank , Financial-services-group-inc , Regenxbio-inc , Northwestern-mutual-wealth-management-co , Company-profile , Headlands-technologies , Nasdaq , Technology-platform